#United States #San Diego #Viking Therapeutics #VK2735 #Dorothy Gemmell

Viking Therapeutics Welcomes New Board Member

In a strategic move to enhance its leadership team, Viking Therapeutics, Inc. has announced the appointment of Dorothy Gemmell to its Board of Directors. This decision comes as Viking, a clinical-stage biopharmaceutical company, seeks to advance its innovative therapies aimed at treating metabolic and endocrine disorders.

A Wealth of Experience

Dorothy Gemmell is no stranger to the healthcare industry. With over 25 years of extensive experience in healthcare, digital health, and commercialization, she stands out as a significant asset to Viking. Over the years, Ms. Gemmell has held key positions, including president and chief commercial officer at prominent companies such as GoodRx and Capsule. Her track record of leading growth initiatives, scaling operations, and constructing revenue models across diverse markets speaks volumes about her capabilities.

Furthermore, Ms. Gemmell has played a critical role advising both venture-backed and private equity-backed firms. Her insights into go-to-market strategies and enterprise sales are invaluable as Viking navigates a competitive landscape for pharmaceutical innovation. Ms. Gemmell’s academic background is equally impressive; she earned her Bachelor of Science in Biochemistry from McGill University, a foundation that enhances her understanding of the complex therapeutic landscapes Viking operates within.

Strengthening Viking's Future

Brian Lian, the CEO of Viking Therapeutics, expressed enthusiasm regarding Ms. Gemmell's addition: “On behalf of the Board and management team, I am pleased to welcome Dorothy to Viking as a new director. Her expertise comes at a crucial time as we advance our next-generation therapies and prepare for the potential launch of VK2735.” VK2735, the company's leading drug, represents a promising advancement in weight management therapies, designed to meet the needs of millions dealing with obesity-related conditions.

Ms. Gemmell, in her own words, acknowledges the exciting landscape of medical innovation: “Scientific innovation has rapidly reshaped one of healthcare's greatest challenges, creating unprecedented opportunities to improve the health and lives of millions of people living with obesity and other chronic metabolic diseases.” Her focal point will be on enhancing the efficacy of Viking’s therapeutic portfolio, especially around VK2735, which is anticipated to revolutionize the existing weight-loss protocols and related health benefits.

Collaborative Vision

Lawson Macartney, Chairman at Viking, also commented on the addition of Ms. Gemmell to the board, highlighting how her commercial expertise will complement the board's depth in pharmaceutical development. As Viking continues to execute its long-term goals, having a diverse skill set among board members is crucial for navigating the complexities of the biopharmaceutical ecosystem.

The appointment symbolizes not just a strengthening of Viking’s board but also a commitment to innovation and patient care in treating metabolic diseases. As the company embarks on expanding its pipeline, including additional obesity programs and potential treatments for rare genetic disorders, the insights and experience of Ms. Gemmell will undoubtedly support their mission.

About Viking Therapeutics

Viking Therapeutics, Inc. is on a mission to advance a next-generation portfolio of therapies focusing on obesity and associated metabolic diseases. The company is driven by a deep understanding of metabolic biology and rigorous scientific methods, paving the way for innovative therapeutic solutions that promise lasting health improvements. Currently, their lead therapeutic candidate, VK2735, is undergoing evaluation in Phase 3 clinical trials, reflecting Viking’s commitment to pioneering therapies that meet pressing health challenges.

For more comprehensive insights into Viking Therapeutics and their therapeutic advancements, interested individuals can visit www.vikingtherapeutics.com.